Sort
48,018 grants matching “immunotherapy”
Cancer Immunotherapy Clinical Trials
$858,075Christopher Heery · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Pathogenesis and Treatment of Anaphylaxis
$856,825Dean D Metcalfe · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Crystallographic studies of macromolecular structures
$856,445Lars Pedersen · National Institute Of Environmental Health Sciences · ZIA · FY2010 · ES
Novel Targets for Vaccine Therapy
$856,385Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA
CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma
$856,276Swey-Shen Chen · Ige Therapeutics, Inc. · R44 · FY2017 · AI
Liver Cancer Program
$856,127Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Comparative Modeling for the Prevention and Control of Uterine Cancer
$856,073Jason Wright · Columbia University Health Sciences · U01 · FY2023 · CA
Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor
$855,918Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
SPORE in Pancreatic Cancer
$855,582Donald J. Buchsbaum · University Of Alabama At Birmingham · P20 · FY2007 · CA
Quantitative high-throughput methods for antibody fragment optimization and discovery
$855,260Curtis Layton · Protillion Biosciences, Inc. · R44 · FY2022 · GM
Quantitative high-throughput methods for antibody fragment optimization and discovery
$855,260Curtis Layton · Protillion Biosciences, Inc. · R44 · FY2021 · GM
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)
$855,001Zhiyong Yang · Fzata, Inc. · R44 · FY2022 · DK
CARE Network - Madison Clinical Center
$854,770University Of Wisconsin Madison · U10 · FY2004 · HL
Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer
$854,530Vincent Sandanayaka · Nirogyone Therapeutics, Llc · R44 · FY2021 · CA
Regulatory T cells and the tumor microenvironment
$854,385Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · R35 · FY2024 · CA
Developing Novel Therapies for High Risk Pediatric Cancers
$854,306Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma
$853,476Swey-Shen Chen · Ige Therapeutics, Inc. · R44 · FY2016 · AI
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$853,223James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Clinical trials employing cancer vaccine combination therapies
$853,223James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
CARE Network--St. Louis Center
$853,075Washington University · U10 · FY2004 · HL
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host
$853,049Ronald Levy · Stanford University · R35 · FY2019 · CA
PROSTATE CANCER ANTIGEN PRESENTATION BY HLA-E AS A NEW TARGET MECHANISM FOR IMMUNOTHERAPY
$853,041Oregon Health & Science University · · FY2019 · Department of the Army
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers
$852,739Stephen Philip Schoenberger · La Jolla Institute For Immunology · U01 · FY2019 · DE
Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569
$852,568Joan Marie Robbins · Dnatrix, Inc. · R44 · FY2022 · CA
Human Immune Responses to Tumor Antigens for Cancer Vaccine Development
$852,537Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA